In this episode presented by IQVIA, BioSpace's head of insights Lori Ellis discusses the FDA's first draft guidance for AI in ...

Cell and gene therapy leaders say the agency’s decision to remove the Risk Evaluation and Mitigation Strategies that had been ...

Macrocyclic peptides are designed to engage complex targets like biologics but pass through cell membranes like small ...

The pivotal trial for Neurogene's Rett syndrome gene therapy makes use of baseline controls and a rigorous endpoint that ...

Pfizer insists that the discontinuation of the Phase II study was due to recruitment difficulties and was not linked to ...

Protagonist is directly going up against Eli Lilly, which is advancing retatrutide, also a triple-G agonist, in a Phase II ...

Big Pharmas like Eli Lilly, Sanofi and Novartis headed back to the dealmakers table multiple times, with 32 total deals ...

BPL-003 showed “robust” efficacy data in treatment-resistant depression, according to analysts from Jefferies, who noted that the asset could hit peak market sales of $1 billion. The results clear the ...